According to the phase I and II trials, the TIGIT inhibitor tiragolumab alone or in combination with the PD-L1 inhibitor atezolizumab, has achieved statistically significant results in the treatment of multiple solid malignancies, most notably non-small cell-lung cancer (27, 28). The gene discussed is TIGIT; the disease is non-small cell lung carcinoma.